Vaccine trial for children with CMV after stem cell transplant
Treatments studied
Part of Infections clinical trials.
This trial studies a vaccine designed to help the body fight cytomegalovirus (CMV) in children who test positive for CMV and are about to receive a donor stem cell transplant. If it works, it may reduce CMV-related illness during recovery after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child has CMV infection detected (CMV blood test positive) around the time of transplant
- Child is planning a donor stem cell transplant soon (not a cord blood transplant), with specific donor match requirements
- The stem cell donor blood is not treated to remove T-cells (no “T-cell depleted” graft)
- No prior investigational CMV vaccine, and no CMV antiviral treatment in the last 6 months
- Child can participate for follow-up visits for up to 1 year after transplant
- If the child could become pregnant (or is a sexually active male), they must use reliable birth control during the study and for about 90 days after transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
This trial tests whether giving a CMV vaccine to stem cell donors can help protect recipients from CMV infection after transplant. It is for adults with specific blood cancers who are CMV-positive and have a matched related donor.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
This trial tests an immune cell treatment (CMV-specific cytotoxic T cells) for people with a CMV infection that is not improving despite standard antivirals, or who cannot tolerate them. If eligible, the treatment aims to help the body control the virus after transplant-related immune problems.
This trial tests whether a special antibody treatment (CMV-specific immunoglobulin) can prevent CMV infections in children who have had a stem cell transplant from a donor. It may help protect your child’s immune system during recovery.
This trial tests a vaccine to prevent cytomegalovirus (CMV) infection in people awaiting a first liver transplant. You may be eligible if you have never been infected with CMV and are scheduled to receive a liver transplant within the next 1 to 12 months.
Hear when a new Cytomegaloviral Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.